"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
There have been no reports of overdosage from the oral administration of Nimotop® (nimodipine) . Symptoms of overdosage would be expected to be related to cardiovascular effects such as excessive peripheral vasodilation with marked systemic hypotension. Clinically significant hypotension due to Nimotop® (nimodipine) overdosage may require active cardiovascular support with pressor agents. Specific treatments for calcium channel blocker overdose should also be given promptly. Since Nimotop® (nimodipine) is highly protein-bound, dialysis is not likely to be of benefit.
Last reviewed on RxList: 9/9/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Nimotop Information
Nimotop - User Reviews
Nimotop User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.